Modified siRNA Structure With a Single Nucleotide Bulge Overcomes Conventional siRNA-mediated Off-target Silencing
Modified siRNA Structure With a Single Nucleotide Bulge Overcomes Conventional siRNA-mediated Off-target Silencing
- Research Article
51
- 10.1016/j.cub.2006.01.061
- Mar 1, 2006
- Current Biology
Short Interfering RNA Strand Selection Is Independent of dsRNA Processing Polarity during RNAi in Drosophila
- Research Article
179
- 10.1016/j.molcel.2006.03.034
- May 1, 2006
- Molecular Cell
Recapitulation of Short RNA-Directed Translational Gene Silencing In Vitro
- Research Article
23
- 10.1038/mtna.2012.15
- May 1, 2012
- Molecular Therapy. Nucleic Acids
Small RNA-Mediated Epigenetic Myostatin Silencing
- Research Article
98
- 10.1038/mtna.2011.4
- Jan 1, 2012
- Molecular therapy. Nucleic acids
siRNA-optimized Modifications for Enhanced In Vivo Activity
- Research Article
101
- 10.1038/mt.2008.288
- Mar 1, 2009
- Molecular Therapy
MicroRNAs and the Regulation of Vector Tropism
- Supplementary Content
25
- 10.1038/mtna.2014.67
- Jan 1, 2015
- Molecular Therapy. Nucleic Acids
In spite of prolonged and intensive treatment with combined antiretroviral therapy (cART), which efficiently suppresses plasma viremia, the integrated provirus of HIV-1 persists in resting memory CD4+ T cells as latent infection. Treatment with cART does not substantially reduce the burden of latent infection. Once cART is ceased, HIV-1 replication recrudesces from these reservoirs in the overwhelming majority of patients. There is increasing evidence supporting a role for noncoding RNAs (ncRNA), including microRNAs (miRNAs), antisense (as)RNAs, and short interfering (si)RNA in the regulation of HIV-1 transcription. This appears to be mediated by interaction with the HIV-1 promoter region. Viral miRNAs have the potential to act as positive or negative regulators of HIV transcription. Moreover, inhibition of virally encoded long-asRNA can induce positive transcriptional regulation, while antisense strands of siRNA targeting the NF-κB region suppress viral transcription. An in-depth understanding of the interaction between ncRNAs and the HIV-1 U3 promoter region may lead to new approaches for the control of HIV reservoirs. This review focuses on promoter associated ncRNAs, with particular emphasis on their role in determining whether HIV-1 establishes active or latent infection.
- Research Article
120
- 10.1074/jbc.m501591200
- Apr 1, 2005
- Journal of Biological Chemistry
Small interfering RNA (siRNA) duplexes induce the specific cleavage of target RNAs in mammalian cells. Their involvement in down-regulation of gene expression is termed RNA interference (RNAi). It is widely believed that RNAi predominates in the cytoplasm. We report here the co-existence of cytoplasmic and nuclear RNAi phenomena in primary human myotonic dystrophy type 1 (DM1) cells by targeting myotonic dystrophy protein kinase (DMPK) mRNAs. Heterozygote DM1 myoblasts from a human DM1 fetus produce a nuclear retained mutant DMPK transcript with large CUG repeats ( approximately 3,200) from one allele of the DMPK gene and a wild type transcript with 18 CUG repeats, thus providing for both a nuclear and cytoplasmic expression profile to be evaluated. We demonstrate here for the first time down-regulation of the endogenous nuclear retained mutant DMPK mRNAs targeted with lentivirus-delivered short hairpin RNAs (shRNAs). This nuclear RNAi(-like) phenomenon was not observed when synthetic siRNAs were delivered by cationic lipids, suggesting either a link between processing of the shRNA and nuclear import or a separate pathway for processing shRNAs in the nuclei. Our observation of simultaneous RNAi on both cytoplasmic and nuclear retained DMPK has important implications for post-transcriptional gene regulation in both compartments of mammalian cells.
- Research Article
379
- 10.1016/j.cell.2006.04.025
- Jun 1, 2006
- Cell
Tethering RITS to a Nascent Transcript Initiates RNAi- and Heterochromatin-Dependent Gene Silencing
- Research Article
56
- 10.1038/sj.mt.6300298
- Jan 1, 2008
- Molecular Therapy
Expression of Long Anti-HIV-1 Hairpin RNAs for the Generation of Multiple siRNAs: Advantages and Limitations
- Research Article
104
- 10.1016/j.molcel.2019.11.012
- Dec 31, 2019
- Molecular Cell
Su(var)2-10 and the SUMO Pathway Link piRNA-Guided Target Recognition to Chromatin Silencing.
- Research Article
314
- 10.1016/j.molcel.2010.05.014
- Jun 3, 2010
- Molecular Cell
In Vitro Assembly of Plant RNA-Induced Silencing Complexes Facilitated by Molecular Chaperone HSP90
- Research Article
11
- 10.1074/mcp.m900614-mcp200
- Sep 1, 2010
- Molecular & Cellular Proteomics
The Drosophila melanogaster RNA-induced silencing complex (RISC) forms a large ribonucleoprotein particle on small interfering RNAs (siRNAs) and catalyzes target mRNA cleavage during RNA interference (RNAi). Dicer-2, R2D2, Loquacious, and Argonaute-2 are examples of RISC-associated factors that are involved in RNAi. Holo-RISC is an approximately 80 S small interfering ribonucleoprotein, which suggests that there are many additional proteins that participate in the RNAi pathway. In this study, we used siRNA affinity capture combined with mass spectrometry to identify novel components of the Drosophila RNAi machinery. Our study identified both established RISC components and novel siRNA-associated factors, many of which contain domains that are consistent with potential roles in RNAi. Functional analysis of these novel siRNA-associated proteins suggests that these factors may play an important role in RNAi.
- Research Article
210
- 10.1038/mtna.2011.5
- Jan 1, 2012
- Molecular Therapy - Nucleic Acids
Targeting DNA With Fingers and TALENs.
- Research Article
114
- 10.1074/jbc.m110.109314
- May 1, 2010
- Journal of Biological Chemistry
Moloney leukemia virus 10 (MOV10) protein is a superfamily-1 RNA helicase, and it is also a component of the RNA-induced silencing complex. Recent studies have shown that MOV10 plays an active role in the RNA interference pathway. Here, we report that MOV10 inhibits retrovirus replication. When it was overexpressed in viral producer cells, MOV10 was able to reduce the infectivity of human immunodeficiency virus type 1 (HIV-1), simian immunodeficiency virus, and murine leukemia virus. Conversely, when MOV10 expression was reduced by small interfering RNAs, HIV-1 infectivity was increased. Consistently, silencing of MOV10 expression in a human T cell line enhanced HIV-1 replication. Furthermore, we found that MOV10 interacts with HIV-1 nucleocapsid protein in an RNA-dependent manner and is packaged into virions. It blocks HIV-1 replication at a postentry step. In addition, we also found that HIV-1 could suppress MOV10 protein expression to counteract this cellular resistance. All of these results indicate that MOV10 has a broad antiretroviral activity that can target a wide range of retroviruses, and it could be actively involved in host defense against retroviral infection.
- Research Article
53
- 10.1016/j.pedneo.2011.08.002
- Nov 6, 2011
- Pediatrics & Neonatology
Rett Syndrome: From Bed to Bench
- Ask R Discovery
- Chat PDF
AI summaries and top papers from 250M+ research sources.